Items Tagged ‘DCIS’

January 20th, 2016

Quality of Life Helps Determine Type of Hormone Treatment in Early Breast Cancer

By

Quality of life issues and different side effects caused by treatment may help determine which type of hormone therapy is most appropriate for postmenopausal women with ductal carcinoma in situ, particularly among women 60 years of age or older. These results were recently published in The Lancet. Hormone-positive breast cancers, which comprise approximately 75% of […]

View full entry

Tags: anastrozole, Arimidex, Breast Cancer, Carcinoma In Situ Breast cancer, DCIS, News, tamoxifen


October 1st, 2015

Radiation Essential to Controlling Long-Term Recurrence in Women With Early Form of Breast Cancer

By

Doctors have reported that rates of breast cancer recurrences continue to increase, even after 12 years, among patients with ductal carcinoma in situ (DCIS) who do not receive radiation therapy as part of their treatment regimen. These results were recently published in the Journal of Clinical Oncology. DCIS is considered to be the earliest type […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, DCIS, News, radiation, recurrence, Recurrent Breast Cancer, study


September 1st, 2015

Women with Early Breast Cancer Have Fewer Side Effects with Shorter Courses of Radiation

By

Women with early breast cancer have fewer side effects when they’re treated with shorter courses of radiation at higher doses than with conventional radiation to the whole breast. These findings were reported in JAMA Oncology.[1] Treatment with shorter course of radiation at higher doses is known as hypofractionated radiation therapy. This approach allows for less […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, conventional radiation, DCIS, hypofractionated radiation therapy, News, radiation, Stage I, Stage I Node Negative Breast Cancer, Stage II, Stages II-III Breast Cancer


August 27th, 2015

Breast Cancer Research and Treatment Publishes Oncotype DX(R) DCIS Score(TM) Study Conducted in Canada

By

Genomic Health, Inc. (Nasdaq: GHDX) announced that Breast Cancer Research and Treatment published results from a second large clinical validation study of Oncotype DX® in patients with stage 0 breast cancer, also known as DCIS (Ductal Carcinoma In Situ). The population-based study, conducted by the Ontario DCIS Study Group, reconfirmed that the Oncotype DX DCIS […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, clinical trial, DCIS, genomic study, News, personalized treatment


June 9th, 2015

Arimidex® More Effective than Tamoxifen in Prevention of Recurrence in Early Breast Cancer

By

For patients with a common type of breast cancer known as ductal carcinoma in situ (DCIS), the drug Arimidex® (anastrozole) may provide better protection against recurrence than tamoxifen. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the Journal of Clinical […]

View full entry

Tags: anastrozole, Arimidex, Breast Cancer, Carcinoma In Situ Breast cancer, DCIS, ductal carcinoma in situ, News, tamoxifen